Peripheral T-cell lymphoma

Updated: July 4, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

belinostat

1000

mg/m^2

Solution

Intravenous (IV)

once a day

on days 1 and 5 of a 21-days cycle.

Dose Adjustments

Reduce belinostat dose by 25% (up to 750 mg/m2) for following conditions: ANC <25,000/mm3 Any grade 3 or 4 recurrent toxicity Discontinue treatment: ANC < 500/mm3 and recurrent nadir platelets < 25,000/mm3.

pralatrexate

mg/m^2

Intravenous (IV)

once weekly for 6 – 7 weeks cycle; continue until unacceptable toxicity or disease progression.

romidepsin

Indicated for the treatment of CTCL and peripheral T-cell lymphoma (PTCL) in patients who have received at least one before systemic therapy :

mg/m^2

Intravenous (IV)

over 4 hr

on days 1, 8, and 15 for a 28-day cycle course
Continue to repeat the cycle every 28 days till the patient's disease progression or intolerable toxicity occurs

alitretinoin topical

Apply every 12 hours to the cutaneous lesion

Future Trends